Stiefel Laboratories to acquire Barrier Therapeutics

Coral Gables, Fla.

- Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.

The transaction is valued at approximately $148 million, and is subject to valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions.